Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10969708 | 0.91 | TSHR (0.45) | TSHRMEN1KMT2ARECQLGAA | |
| SCHEMBL12313843 | 0.87 | TSHR (0.46) | TSHRMAPK1MEN1KMT2AACHE | |
| SCHEMBL20822014 | 0.85 | MEN1 (0.48) | TSHRMAPK1MEN1KMT2AACHE | |
| SCHEMBL26551714 | 0.84 | TSHR (0.44) | TSHRMEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL13955338 | 0.82 | TSHR (0.43) | TSHRMEN1KMT2ARECQLALDH1A1 | |
| SCHEMBL5143610 | 0.82 | RAB9A (0.54) | TSHRMEN1KMT2AALDH1A1HTT | |
| SCHEMBL18471595 | 0.81 | TSHR (0.46) | TSHRMAPK1ACHERECQLGAA | |
| SCHEMBL19306452 | 0.81 | TSHR (0.43) | TSHRMAPK1MEN1KMT2AACHE | |
| SCHEMBL20115945 | 0.80 | MEN1 (0.45) | TSHRMAPK1MEN1KMT2AGAA | |
| SCHEMBL22932088 | 0.80 | TSHR (0.41) | TSHRMEN1KMT2ARECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987369-B2 | Vitamin functionalized gel-forming block copolymers for biomedical applications | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987369-B2 | Vitamin functionalized gel-forming block copolymers for biomedical applications | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2018-06-05 | — | — | US | disclosed |
| US-20180117162-A1 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117162-A1 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS | VDR, PROC, CYP24A1 | TSHR 4141/4885MAPK1 3853/4885MEN1 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.